Health
Fidson shareholders approve N3.6bn dividend after record N119bn revenue
Shareholders of the largest pharmaceutical company in Nigeria, Fidson Healthcare Plc, have approved a dividend of ₦1.50 per 50 kobo ordinary share, amounting to ₦3.6 billion.
The company explained that the approved N3.6bn dividend reflects shareholders’ confidence in the company’s ability to deliver sustainable value despite a challenging operating environment.
The approval was made at the company’s 27th Annual General Meeting held virtually on July 30, 2026.
Aside from approving the dividend, the election and re-election of directors, authorisation to fix auditors’ remuneration, and the election of members of the Statutory Audit Committee were other resolutions that shareholders considered and approved at the AGM.
In his address to shareholders, the Founder and Chairman of Fidson Healthcare Plc, Dr. Fidelis Ayebae, said 2025 marked a defining year in the company’s history.
According to him, Fidson became the first pharma company in Nigeria to surpass N100 billion annual revenue.
“We recorded revenue of N119.06 billion, becoming the first pharmaceutical company in Nigeria to surpass the N100 billion annual revenue milestone.
“This achievement reflects the dedication of our people, the confidence of our shareholders, and the effectiveness of our long-term growth strategy,” Ayebae said.
He added that, beyond financial performance, the company continued to make strategic investments that will shape the future of healthcare manufacturing in Africa.
Ayebae said, “Our ongoing expansion projects have reached advanced stages and, upon completion, will position Fidson as the largest and most sophisticated pharmaceutical manufacturing company in Sub-Saharan Africa.
“We are confident that Fidson is well-positioned to deliver sustainable growth, deepen healthcare access, and continue to create superior value for our shareholders and all stakeholders.”
Recognising critical enablers of the business, Ayebae commended the Federal Government for improving the operating environment for local pharmaceutical manufacturers.
He noted that through strategic policies, the FG has strengthened industry players like Fidson to meet the high demand for pharma products at affordable prices for Nigerians.
Responding to questions and comments from shareholders, the Managing Director/Chief Executive Officer of Fidson Healthcare Plc, Mr. Biola Adebayo, reaffirmed the company’s commitment to sustaining growth through innovation, manufacturing excellence, and strategic investments.
“Our focus remains clear—to deepen our manufacturing capabilities, widen our product portfolio, improve market penetration, and build a healthcare institution that delivers value to consumers, healthcare professionals, shareholders, and society at large.
“We will achieve this by leveraging emerging opportunities across Africa and continually strengthening our processes for sustainable growth,” he said.
Shareholders who spoke during the meeting commended the Board and Management for maintaining the company’s growth trajectory and dividend policy that rewards investors while preserving adequate resources for future expansion.
They also expressed confidence in management’s ability to build on existing achievements and further strengthen Fidson’s position as a leading pharmaceutical manufacturing company in Nigeria.
The meeting also underscored Fidson’s continued commitment to improving shareholder engagement through electronic annual reports, e-dividend platforms, and virtual participation in its Annual General Meeting, enabling shareholders to engage more conveniently in the company’s affairs.
The company reiterated its commitment to its vision of adding value to lives through quality pharmaceutical products while delivering sustainable returns to shareholders and contributing meaningfully to the development of Africa’s healthcare ecosystem.
Copyright PUNCH
All rights reserved. This material, and other digital content on this website, may not be reproduced, published, broadcast, rewritten, or redistributed in whole or in part without prior express written permission from PUNCH.
Contact: health_wise@punchng.